Evidence map›Paper›PMID 31953535›Full record

ReviewNature reviews. Cardiology2020

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Davide Capodanno, Deepak L Bhatt, John W Eikelboom, Keith A A Fox, Tobias Geisler, C Michael Gibson, Jose Ramon Gonzalez-Juanatey, Stefan James, Renato D Lopes, Roxana Mehran and 9 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 119 citations in OpenAlex.

  1. Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antithrombotic therapy in complex percutaneous coronary intervention.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Review
  16. Article
  17. Bibliometric analysis of residual cardiovascular risk: trends and frontiers.Journal of health, population, and nutrition · 2023
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 18 institutions in 9 countries.

Davide CapodannoDivision of Cardiology, C.A.S.T., P.O. 'G. Rodolico', Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', University of Catania, Catania, Italy.
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1278-6245
John W EikelboomPopulation Health Research Institute, Hamilton General Hospital and McMaster University, Hamilton, ON, Canada.
Keith A A FoxCentre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-0140-2752
Tobias GeislerDepartment of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
C Michael GibsonCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4857-9125
Jose Ramon Gonzalez-JuanateyCardiology Department, University Hospital, IDIS, CIBERCV, Santiago de Compostela, Spain.
Stefan JamesDepartment of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Renato D LopesDivision of Cardiology, Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Roxana MehranCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gilles MontalescotSorbonne Université, ACTION Study Group, Institut de Cardiologie, Pitié Salpêtrière Hôpital (AP-HP), Paris, France.
Manesh PatelDivision of Cardiology, Duke Clinical Research Institute, Duke University, Durham, NC, USA.
P Gabriel StegAssistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris University, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France.
Robert F StoreyDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Pascal VranckxDepartment of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, and Faculty of Medicine and Life Sciences at the University of Hasselt, Hasselt, Belgium.
Jeffrey I WeitzDepartments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.
Robert WelshCardiac Sciences Department, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, AL, Canada.
Uwe ZeymerKlinikum Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen, Germany.
Dominick J AngiolilloDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA. dominick.angiolillo@jax.ufl.edu.ORCID http://orcid.org/0000-0001-8451-2131
Duke University · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCardiovascular Institute of the South · USCentro de Investigación en Red en Enfermedades Cardiovasculares · ESHamilton General Hospital · CAHartcentrum Hasselt · BEInserm · FRKlinikum Ludwigshafen · DESorbonne Université · FRThrombosis and Atherosclerosis Research Institute · CAUniversity Children's Hospital Tübingen · DEUniversity of Alberta · CAUniversity of Catania · ITUniversity of Edinburgh · GBUniversity of Florida · USUniversity of Sheffield · GBUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease.

Indexed as

AnticoagulantsCardiovascular DiseasesDrug Therapy, CombinationFactor Xa InhibitorsFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsThrombosisAnticoagulantsFactor Xa InhibitorsFibrinolytic AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID31953535
OpenAlexW2999002463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.